ResMed (RMD) has been on a downward spiral lately with significant selling pressure. After declining 12% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator t ...

ResMed (RMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings pict ...

Core Insights - Resmed Inc. (RMD) is expanding its mask portfolio through innovation and targeted initiatives, benefiting from the global supply of AirSense10 and AirSense11 platforms, while maintaining sufficient liquidity to meet short-term obligations [1][2] Financial Performance - RMD's stock has increased by 4.7% over the past year, contrasting with a 20.4% decline in the industry and a 21.5% growth in the S&P 500 [2] - The company has a market capitalization of $33.63 billion and an earnings yield of 4.8%, outperforming the industry's yield of 2.8% [2] - RMD has consistently surpassed earnings estimates over the past four quarters, achieving an average surprise of 2.74% [2] Revenue Growth - Mask revenues grew by 16% year-over-year in Q2 of fiscal 2026, driven by strategic expansion and increased resupply efforts [3][8] - Device sales also contributed to revenue growth, with global constant-currency sales increasing by 7% in Q2 of fiscal 2026, including 8% growth in the U.S., Canada, and Latin America [5] - The company acquired VirtuOx, contributing to incremental revenues, and launched new variants of the AirTouch F30i mask platform [4] Solvency and Debt Management - Resmed ended Q2 of fiscal 2026 with cash and cash equivalents of $1.42 billion and current debt of $260 million, with long-term debt decreasing by 1.2% to $404 million [9] - The debt-to-capital ratio was 6%, reflecting a 0.3% decrease sequentially, indicating strong solvency [9] Market Challenges - Resmed faces macroeconomic challenges, including geopolitical instability and supply chain constraints, which could impact product demand and operating costs [10] - The competitive landscape for sleep-disordered breathing (SDB) products is intense, with potential difficulties arising from competitors being affiliates of its customers [11] Earnings Projections - The Zacks Consensus Estimate for RMD's fiscal 2026 earnings per share is projected at $10.98, with revenues expected to reach $5.62 billion, reflecting a 9.2% increase year-over-year [12]

Core Viewpoint - ResMed (RMD) has faced significant selling pressure, resulting in an 8.7% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1]. Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2]. - RMD's current RSI reading is 28.12, suggesting that the heavy selling may be nearing exhaustion, potentially leading to a price rebound [5]. Group 2: Fundamental Analysis - Analysts have raised earnings estimates for RMD, with a 0.1% increase in the consensus EPS estimate over the last 30 days, indicating a positive trend that often correlates with price appreciation [7]. - RMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, further supporting the potential for a turnaround [8].

Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU markets. I like to delve into clinical catalysts or play earnings on new drug launches. I do not provide personal investment advice. All content that I provide, including but not limited to opinions, analyses, commentaries, forecasts, stock picks, and investment strategies, is for informational and educational purposes only and should not be interpre ...

Company Overview - ResMed Inc. (RMD) is a San Diego-based company that manufactures, distributes, and markets medical devices and cloud-based software applications, with a market cap of $36 billion [1] - The company specializes in products for respiratory disorders, including diagnostic tools, cloud-based patient monitoring platforms, and out-of-hospital software solutions [1] Market Position - RMD is classified as a large-cap stock, reflecting its significant size and influence in the medical instruments & supplies industry [2] - The company's competitive advantage lies in its diversified portfolio in sleep and respiratory care, strong brand recognition, and technological innovations such as AI-powered therapy and remote monitoring [2] - ResMed operates in over 140 countries, leveraging its global presence to maintain its market leadership [2] Stock Performance - RMD's stock has experienced an 18.3% decline from its 52-week high of $293.81, reached on August 22, 2025 [3] - Over the past three months, RMD stock has decreased by 4.9%, underperforming the Nasdaq Composite's 3.7% losses during the same period [3] - Year-to-date, RMD shares have fallen slightly, outperforming the Nasdaq's YTD losses of 2.3%, but the stock has only increased by 6.4% over the past 52 weeks, significantly lagging behind the Nasdaq's 30.3% returns [3] Technical Analysis - RMD has been trading below its 200-day moving average since late October 2025, indicating a bearish trend, and is also trading below its 50-day moving average recently [4] Financial Performance - In its Q2 results, RMD reported an adjusted EPS of $2.81, exceeding Wall Street's expectations of $2.69, and revenue of $1.42 billion, surpassing forecasts of $1.39 billion [5] - In comparison, Baxter International Inc. (BAX) has underperformed RMD, with a 5.6% decline year-to-date and a 49.7% drop over the past 52 weeks [5]

Company Overview - ResMed is a leading company in the respiratory care devices sector, producing equipment like CPAP machines that assist millions with sleep apnea and COPD, claiming to have improved over 144 million lives in the past year [2] Growth Performance - ResMed has a market value of nearly $38 billion and has averaged annual stock gains of 15.6% over the past 15 years and 16.9% over the past 10 years, although growth has slowed to an average of 6.5% over the last three years [3] - The company reported a year-over-year revenue increase of 11% in Q2 of fiscal 2026, with gross profit margins and income from operations rising by 18% [4] Strategic Investments - ResMed is focusing on innovation and digital health technologies to enhance growth, with investments in next-generation masks, cloud-connected devices, and digital healthcare software [6][7] - The CEO highlighted the importance of their digital health ecosystem, which spans over 140 countries, in driving demand for their products [5]

Company Updates - The Walt Disney Company has appointed Josh D'Amaro as CEO, succeeding Bob Iger on March 18, while Kristina Schake will depart the company after the same date [1] - Toast, Inc. reported fourth-quarter earnings of 16 cents per share, exceeding the analyst consensus estimate of 13 cents per share, with quarterly sales of $1.633 billion, surpassing the estimate of $1.620 billion [2] - ServiceNow, Inc. reported fourth-quarter revenue of approximately $3.57 billion, beating the consensus estimate of $3.53 billion, and adjusted earnings of 92 cents per share, exceeding analyst estimates of 88 cents per share [3] - ResMed Inc. posted better-than-expected earnings and sales results for its second quarter [4] Stock Performance - Toast shares increased by 5.6% to close at $29.11 [5] - Disney shares decreased by 1% to settle at $103.30 [5] - ServiceNow shares rose by 3.5% to close at $113.19 [5] - ResMed shares gained 0.4% to settle at $258.28 [5]

Core Insights - Global sleep health awareness is increasing, but there is a significant action gap where individuals recognize the importance of sleep yet fail to take steps to improve their sleep quality [2][3][10] Awareness and Action Gap - 53% of respondents consider sleep the most important factor for long-term health, surpassing diet and exercise, yet many do not take meaningful actions to enhance their sleep [2][7] - 84% of respondents acknowledge that consistent, quality sleep can extend a healthy lifespan, but 53% report getting quality sleep only four nights a week or less [3][7] Opportunities for Improvement - There is a clear opportunity to enhance education, screening, and diagnosis to help individuals identify sleep issues earlier and access care pathways [5] - The rise in wearable technology for sleep tracking has increased awareness, with usage among respondents growing from 16% in 2025 to 53% in 2026 [8] Gender Disparities - Nearly half of women surveyed (48%) struggle to fall asleep, an increase from 38% in 2025, with stress and anxiety being significant barriers [9] - Family responsibilities negatively impact sleep for 39% of women compared to 33% of men, highlighting a gender gap in sleep quality [9] Mental Health Connection - Insufficient sleep is linked to higher risks of anxiety and depression, with over a third of respondents reporting increased irritability (36%) and stress (33%) after poor sleep [9] Workplace Impact - More than half of respondents (58%) believe heavy workloads negatively affect their sleep, and 70% report taking a "snooze day" after a poor night's sleep [9] Relationship Dynamics - Sleeping together is associated with stronger intimacy, with 53% of respondents noting a positive impact on their sex life, although 80% experience some level of partner-related sleep disruption [9]

Core Insights - The 2026 Resmed Global Sleep Survey indicates a growing awareness of sleep health globally, yet a significant action gap persists between recognizing the importance of sleep and taking steps to improve sleep quality [2][3][4]. Awareness and Action Gap - Over half (53%) of respondents consider sleep the most important factor for long-term health, surpassing diet and exercise, but many do not take meaningful actions to enhance their sleep [2][7]. - Despite 84% of respondents acknowledging that quality sleep can extend a healthy lifespan, 53% report achieving a good night's sleep only four nights a week or less, illustrating the disconnect between awareness and action [3][4]. Opportunities for Improvement - The findings highlight a clear opportunity for enhanced education, screening, and diagnosis to help individuals identify sleep issues earlier and access appropriate care pathways [5]. - Increased use of wearable technology for sleep tracking has surged from 16% in 2025 to 53% in 2026, with 62% of wearable users indicating they would seek medical advice if their device flagged a potential risk [8]. Gender Disparities - Nearly half (48%) of women surveyed struggle to fall asleep, an increase from 38% in 2025, with stress and anxiety cited as significant barriers [9]. - Family responsibilities negatively impact sleep for 39% of women compared to 33% of men, further widening the gender gap in sleep quality [9]. Mental Health and Sleep - Insufficient sleep is linked to higher risks of anxiety and depression, with over a third of respondents reporting increased irritability (36%) and stress (33%) after poor sleep [9]. - A quarter (25%) of respondents globally reported feelings of depression following inadequate sleep [9]. Workplace Impact - More than half (58%) of respondents believe heavy workloads adversely affect their sleep, and 70% have taken a "snooze day" due to poor sleep [9]. - Flexible working arrangements are seen as beneficial by 59% of respondents in managing their sleep [9]. Relationship Dynamics - Sleeping together is associated with improved intimacy, with 53% of respondents noting a positive impact on their sex life, while 39% report their partner interrupts their sleep at least weekly [9].